IPO round-up: CardioDx back on; Lombard gets US listing
This article was originally published in Clinica
Executive Summary
Diagnostic specialist CardioDx has resurrected its IPO plans, but did not give details of how much it hopes to raise. The company already tried to go public last November, targeting five million shares at $14-16 each, but postponed it due to poor market conditions. Before this, it had said it hoped to bring in $86m. It first filed for an IPO in July 2013.